Evaluation of serum cytokines in small cell lung cancer and its clinical significance

It has been proven that serum cytokines could be changed in the early stage of patients with small cell lung cancer (SCLC). The current research investigates the different changes of cytockines and searches for potential biomarkers to improve the situation of the early diagnosis of SCLC. The differential expression cytokines were detected using Reybiotech G6/G7 analysis of microarrays in the serum of 4 SCLC patients, 4 normal controls, and 4 phlegmonosis controls. The differential cytokines were confirmed by enzyme-linked immunosorbentassay (ELISA) in 197 SCLC patients, 180 normal controls, and 97 phlegmonosis controls. The levels of the 4 most valuable biomarkers in SCLC, including Leptin, MSP-α, uPAR, and MIP-1β, were significantly higher than that in the other groups with microaaray screening (P